A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Public ClinicalTrials.gov record NCT02314117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Study identification
- NCT ID
- NCT02314117
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 645 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 20, 2015 (Actual)
- Primary completion
- Jan 17, 2017 (Actual)
- Completion
- Aug 14, 2020 (Actual)
- Last update posted
- Aug 26, 2021
2015 – 2020
United States locations
- U.S. sites
- 25
- U.S. states
- 13
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Fayetteville | Arkansas | 72703 | — |
| Comprehensive Blood and Cancer Center | Bakersfield | California | 93309 | — |
| St Jude Medical Center | Fullerton | California | 92835 | — |
| SMO TRIO -Translational Research | Los Angeles | California | 90024 | — |
| UCLA Medical Center | Los Angeles | California | 90024 | — |
| Cancer Care Associates Medical Group | Redondo Beach | California | 90277 | — |
| Coastal Integrative Cancer Care | San Luis Obispo | California | 93401 | — |
| Central Coast Medical Oncology Corporation | Santa Monica | California | 93454 | — |
| University of Colorado School of Medicine | Aurora | Colorado | 80045 | — |
| Yale University School of Medicine | New Haven | Connecticut | 06520-8020 | — |
| Holy Cross Hospital Inc. | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists and Research Institute | St. Petersburg | Florida | 33705 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Illinois CancerCare | Peoria | Illinois | 61615 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Weill Cornell Medical College | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| SMO Sarah Cannon Research Inst. | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| UT Southwestern Med Ctr | Dallas | Texas | 75390 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02314117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02314117 live on ClinicalTrials.gov.